source
- Akeso and Summit report ivonescimab meets overall survival endpoint in Phase 3 lung cancer trialAkeso and its partner Summit said the Phase 3 trial of ivonescimab, a PD-1xVEGF bispecific antibody, has met its overall survival endpoint in a selected group of lung cancer patients. The announcem…
- AbbVie reports 60% reduction in progression risk for myeloma drug etentamig in Phase 3 trialAbbVie announced results from a Phase 3 study of its T cell engager etentamig in patients with multiple myeloma. The trial demonstrated a 60% relative reduction in the risk of disease progression…